ReviewFrontiers in immunology2025
Progress in research on predictors of adverse outcomes in patients with nasal inflammatory diseases.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasal inflammatory disease has a complex pathogenesis, high incidence and long disease course. Complete resolution is often challenging, and these diseases are closely related to upper and lower respiratory tract diseases. For common nasal inflammatory diseases, such as chronic rhinosinusitis (CRS), allergic rhinitis (AR), and fungal rhinosinusitis (FRS), adverse outcomes, such as repeated inflammation, AR combined with asthma, and postoperative recurrence, often occur despite standardized treatments, causing great distress to patients and increasing societal costs due to the need for long-term and repeated treatments. Therefore, the identification of early predictors of unfavorable outcomes of nasal inflammatory diseases is important for achieving early diagnosis, intervention and treatment of nasal inflammatory diseases. This paper summarizes the progress in research on the role of indicators, such as inflammatory cytokines, inflammatory cells, metabolites, nasal flora, and clinical parameters, in predicting poor outcomes in patients with nasal inflammatory diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.